ArticleEBioMedicine2026
Sustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
backgroundAlthough antigenemia is associated with poor outcomes in respiratory viral infections, the underlying mechanisms driving viral bloodstream dissemination remain not fully understood. Herein, we aimed to characterise SARS-CoV-2 nucleocapsid (N)-antigenemia kinetics in patients with severe COVID-19. We also sought to identify host and viral determinants associated with viral dissemination through a multiparametric integrated analysis and assess the associated risk of death.
methodsThis observational study included hospitalised patients with severe COVID-19 across three independent cohorts (discovery, n = 66; confirmation, n = 137; validation, n = 27), used respectively for identification, replication, and validation of findings, along with patients with mild COVID-19 and with severe influenza infection, as a disease severity and non-COVID-19 control group. From blood and nasal samples, N-antigenemia levels were analysed in relation to 45 host/viral parameters. Multivariable logistic regression was performed to assess the association with in-hospital mortality. Single-cell RNA sequencing was used to identify host determinants, and in vitro primary human airway epithelial models were used to assess epithelial barrier integrity and viral translocation.
findingsAcross cohorts, we observed a significantly higher detection rate and concentration of N-antigenemia in patients with severe COVID-19 at admission compared to those with mild COVID-19 or controls (fold change [FC] >54.7, p < 0.001 [Kruskal-Wallis, Dunn post-hoc]). Type-I interferon (IFN-I) activity was the strongest correlate of N-antigenemia (ρ = 0.72, p.adj < 0.001 [Spearman, Benjamini-Hochberg]), and longitudinal analyses revealed a strong positive sigmoidal relationship (p < 0.001 [approximate Wald test]). Patients with severe COVID-19 with neutralising autoantibodies against IFN-I lacked detectable N-antigenemia, further supporting a link between systemic viral dissemination and IFN-I activity. Single-cell RNA sequencing showed higher expression of interferon-stimulated genes in monocytes and dendritic cells in patients with a high N-antigenemia level. Furthermore, high N-antigenemia at hospital admission was independently associated with an increased risk of death (aOR 2.6, 95% CI 1.0-6.7; p = 0.042 [Wald test]). Finally, we demonstrated that prolonged IFN-I exposure in vitro appears to impair epithelial barrier integrity.
interpretationThese findings suggest that sustained IFN-I activity is associated with systemic viral dissemination and epithelial barrier dysfunction in patient with severe COVID-19. The concordance between clinical observations and in vitro data supports a potential link between prolonged IFN-I responses and these processes, although causality remains to be established. These results highlight the potential importance of the timing and duration of IFN-I immunity and warrant further investigation of its clinical relevance.
fundingAgence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), ANRS Maladies Infectieuses Émergentes (ANRS MIE), Agence Nationale de la Recherche (ANR), Institut National de la Santé et de la Recherche Médicale (INSERM), European Union Horizon 2020 Research and Innovation Programme, CAPNET, and Klinbeforsk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.